Legato-HD Phase 2: A Clinical Trial Update
-
Upload
visualscience -
Category
Science
-
view
225 -
download
4
Transcript of Legato-HD Phase 2: A Clinical Trial Update
![Page 1: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/1.jpg)
vsLAQUINIMOD
A clinical trial update
Phase 2
HUNTINGTONS
![Page 2: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/2.jpg)
In the red corner,the undefeatedHUNTINGTONS
![Page 3: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/3.jpg)
In the blue corner,the new-hopeful
LAQUINIMOD
![Page 4: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/4.jpg)
How will itfight HD?
![Page 5: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/5.jpg)
Laquinomid canchange the activity of
our immune system.
![Page 6: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/6.jpg)
Normally, this helps us fight diseases by
stimulating inflammation.
![Page 7: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/7.jpg)
But, in neurodegenerative diseases too much inflammation might
be a problem...
![Page 8: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/8.jpg)
By slowing down the immune system
laquinomid could slow the progress of Huntingtons.
![Page 9: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/9.jpg)
How do we know this?
![Page 10: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/10.jpg)
By studying another diseasecalled Relapse-Remitting
Multiple Sclerosis...
![Page 11: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/11.jpg)
A disease which getsworse, then betterthen even worseas it advances.
![Page 12: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/12.jpg)
When it gets worse: too much inflammation
is the problem.
![Page 13: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/13.jpg)
Laquinimod is being tested against this disease in
another trial calledConcerto...
![Page 14: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/14.jpg)
Which is already in stage 3.
![Page 15: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/15.jpg)
This experience fighting MSis good preparation for
its fight against Huntingtons.
![Page 16: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/16.jpg)
It gives us crucial information about how it will behave in the ring - our bodies!
![Page 17: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/17.jpg)
(There’s no point supporting laquinimod if it’s going
to do us harm)
![Page 18: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/18.jpg)
What information have we learned about
Laquinimod?
![Page 19: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/19.jpg)
We have learned:How much our bodies
can handle - a safe dose.
![Page 20: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/20.jpg)
Also:What problems our bodies
could have - the side-effects.
![Page 21: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/21.jpg)
This information means the HD-trial has started
in a strong position.
![Page 22: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/22.jpg)
Legato-HD is now on phase 2.
![Page 23: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/23.jpg)
Whats the aim of Phase 2?
![Page 24: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/24.jpg)
To continue checking safety- to see what can we
consume on a daily basis.
![Page 25: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/25.jpg)
To start testing efficacy- to see if it has an
effect on Huntingtons.
![Page 26: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/26.jpg)
How will we know if it has?
![Page 27: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/27.jpg)
By measuring Motor-score: a sign of how well a patient can control their movement.
![Page 28: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/28.jpg)
If this score declines less in patients taking the drug,
Laquinimod is helping!
![Page 29: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/29.jpg)
This is the studies primary end-point:
the trial will only continue if this improves after 12 months.
![Page 30: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/30.jpg)
So, whats the story so far?
![Page 31: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/31.jpg)
By June 2016400 adults - with
and without HD - were meant to be recruited.
![Page 32: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/32.jpg)
They were to receivea daily dose of either:
a placebo, 0.5 mg, 1.0 mg, 1.5 mg.
![Page 33: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/33.jpg)
In Jan 2016,it was decided to stop the 1.5 mg daily dose.
![Page 34: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/34.jpg)
This was because of a recomendation from the
MS study, Concerto...
![Page 35: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/35.jpg)
Some of their patients ona similar 1.2mg dose had heart problems.
![Page 36: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/36.jpg)
As a result, no one new is being recruited to
to take the highest dose.
![Page 37: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/37.jpg)
But, the other 2 doses and placebo are
still running.
![Page 38: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/38.jpg)
The bad news:The recruitment deadline has been pushed back
(delaying the study)
![Page 39: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/39.jpg)
The good news:They will now only need to
recruit 300 patients (one dose is missing)
![Page 40: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/40.jpg)
Conclusion?
![Page 41: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/41.jpg)
In a heavy-weight fight,information like this is
exactly what we need if...
![Page 42: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/42.jpg)
We want to improve the odds of a win for
Laquinimod!
![Page 43: Legato-HD Phase 2: A Clinical Trial Update](https://reader031.fdocuments.us/reader031/viewer/2022021814/58f160e31a28ab19728b45bf/html5/thumbnails/43.jpg)
A visualscience presentation made by @DeLaSouz
for HDYO